The grant of a new U.S. patent typically signifies a competitive edge in technology and intellectual property, which can lead to increased investor confidence and a potential rise in stock price. As the patent is directly related to Aclarion's core business of medical diagnostics, it is highly relevant and important to the company's prospects. The positive impact on the stock price is likely, although market conditions and broader economic factors could also influence the stock's performance.